Physician

Albert B. Empedrad, MD

According to 2025 Medicare claims, Albert Empedrad, MD (NPI: 1699899914) practices endocrinology in the Lakewood-New Brunswick, NJ market, with the plurality of this provider's patient population coming from Middlesex, NJ. This provider's primary affiliated billing organization is MANALAPAN MEDICAL CENTER PA PC (NPI: 1821225137) and primary practice location at 08690-1751.

Empedrad's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 402 traditional Medicare patients, billed 4,695 HCPCS/CPT codes, and received $151,407 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 4,991 prescription claims across 595 beneficiaries totaling $2,475,771 in drug costs, led by Ozempic (Semaglutide). DME data shows 452 claims. Open Payments data shows 24 records totaling $441. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $64,556 and ending at $151,407. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $930,353 to $2,475,771. For DME billing, reported payments rose steadily, from $7,548 to $124,489.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	383	1,244	$64,556
2016	727	1,516	$90,128
2017	881	2,591	$188,083
2018	239	681	$50,429
2019	210	1,039	$81,337
2020	213	1,137	$87,128
2021	246	1,272	$97,841
2022	251	1,075	$80,005
2023	329	2,160	$109,959
2024	402	4,695	$151,407

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	362	3,200	$930,353
2016	427	3,042	$1,030,260
2017	477	2,100	$630,169
2018	273	1,023	$418,000
2019	148	1,023	$407,969
2020	207	1,689	$849,196
2021	282	2,337	$1,146,187
2022	338	2,839	$1,473,290
2023	464	3,907	$2,295,528
2024	595	4,991	$2,475,771

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	309	872	$20,646
2016	323	771	$12,058
2017	160	273	$5,055
2018	100	208	$4,373
2019	77	212	$16,070
2020	82	280	$27,590
2021	103	374	$48,083
2022	103	441	$59,492
2023	116	441	$57,544
2024	172	452	$119,172

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	87	87	$129
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	67	78	$100
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	250	552	$95
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	87	118	$66
95251	Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report	120	284	$26

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	424	18,284	$577,516
Mounjaro	Tirzepatide	253	9,302	$339,842
Jardiance	Empagliflozin	128	8,714	$165,762
Januvia	Sitagliptin Phosphate	146	8,805	$156,408
Trulicity	Dulaglutide	119	4,616	$151,280

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	63	239	$107,109
E2103	Non-adjunctive, non-implanted continuous glucose monitor or receiver	N	23	23	$4,688
E0784	External ambulatory infusion pump, insulin	Y	N/R	13	$4,444
A4253	Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips	N	57	115	$2,754
A4259	Lancets, per box of 100	N	29	45	$116

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	24	$441	Novo Nordisk Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Albert B. Empedrad, MD?

Tedicare shows public-source Medicare data for Albert B. Empedrad, MD (NPI 1699899914), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Albert B. Empedrad, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Albert B. Empedrad, MD?

Albert B. Empedrad, MD is linked to MANALAPAN MEDICAL CENTER PA PC (billing NPI 1821225137) in the available physician profile data.

Does Albert B. Empedrad, MD have Open Payments data?

Albert B. Empedrad, MD has 24 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.